Evidence map›Paper›PMID 40673866›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

The Evolutionary Trajectory and Prognostic Value of GITR+ Tregs Reprogramed by Tumor-Intrinsic PD-1/c-MET Signaling in Pancreatic Cancer.

Jiande Han, Hanlin Yin, Taochen He, Junyi He, Zhenlai Jiang, Qiangda Chen, Zhihang Xu, Yuqi Xie, Yaolin Xu, Haibo Wang and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jiande HanDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Hanlin YinDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Taochen HeDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Junyi HeDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Zhenlai JiangDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Qiangda ChenDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Zhihang XuDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yuqi XieDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yaolin XuDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Haibo WangMedical College of Yangzhou University, Yangzhou, 225002, China.
Wenquan WangDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Wenchuan WuDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yun JinDepartment of Hepatobiliary and Pancreatic Surgery, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650500, China.
Wenhui LouDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Jun YuPancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
Ning PuDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Liang LiuDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.ORCID 0000-0003-3435-6550

Funding

Beijing Xisike Clinical Oncology Research Foundation Y-2022METAZQN-0003Beijing Xisike Clinical Oncology Research Foundation Y-Gilead2024-PT-0002Beijing Xisike Clinical Oncology Research Foundation Y-HR2022MS-0251Beijing Xisike Clinical Oncology Research Foundation Y-HR2022QN-0085Fund of Fujian Provincial Key Laboratory of Translational Cancer Medicine TCM2024-2National Natural Science Foundation of China 82103409National Natural Science Foundation of China 82103417National Natural Science Foundation of China 82272929National Natural Science Foundation of China 82273382National Natural Science Foundation of China 82303443National Natural Science Foundation of China 82473459Open Research Fund of Key Laboratory of Gastrointestinal CancerProgram of Shanghai Academic/Technology Research Leader 23XD1400600Science and Technology Planning Project of Yunnan Province 202305AF150148Shanghai Municipal Health Commission 201940019Shanghai Municipal Health Commission 20244Y0023Shanghai Science and Technology Commission Innovative Pharmaceutical Products Application Demonstration Project 24SF1900300
6 · The paper itself

Abstract

Tumor-intrinsic programmed cell death 1 (PD-1) has been shown to activate the mesenchymal epithelial transition factor (MET) pathway via its phosphorylation in pancreatic ductal adenocarcinoma (PDAC). However, the immunoregulatory consequences of MET activation remain poorly understood. Herein, a significant positive correlation between phosphorylated MET (p-MET) and tumor-intrinsic PD-1 is verified, both of which are independently associated with adverse prognosis. Elevated p-MET levels correlated with diminished CD8

Indexed as

Carcinoma, Pancreatic DuctalGlucocorticoid-Induced TNFR-Related ProteinPancreatic NeoplasmsProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-metT-Lymphocytes, RegulatoryAnimalsFemaleHumansMaleMicePrognosisSignal TransductionGlucocorticoid-Induced TNFR-Related ProteinMET protein, humanPDCD1 protein, humanProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-metTNFRSF18 protein, humanGITRMETpancreatic ductal adenocarcinomaprognosisregulatory T cellstumor‐intrinsic PD‐1

Identifiers

PMID40673866
PMCPMC12463103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.